{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Infusion+of+CD34+selected+hematopoietic+stem+cells",
    "query": {
      "intervention": "Infusion of CD34 selected hematopoietic stem cells"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 52,
    "total_pages": 6,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Infusion+of+CD34+selected+hematopoietic+stem+cells&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-10-01T12:16:51.584Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT00692939",
      "title": "Autologous Stem Cell Transplantation for Crohn's Disease",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Crohn's Disease"
      ],
      "interventions": [
        {
          "name": "autologous CD34-selected peripheral blood stem cells transplant",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Alemtuzumab",
          "type": "DRUG"
        },
        {
          "name": "ATG",
          "type": "DRUG"
        },
        {
          "name": "Melphalan",
          "type": "DRUG"
        },
        {
          "name": "Thiotepa",
          "type": "DRUG"
        },
        {
          "name": "Rituximab",
          "type": "DRUG"
        },
        {
          "name": "Cyclophosphamide",
          "type": "DRUG"
        },
        {
          "name": "G-CSF",
          "type": "DRUG"
        },
        {
          "name": "Mesna",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "Paul Szabolcs",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "10 Years",
        "maximum_age": "60 Years",
        "sex": "ALL",
        "summary": "10 Years to 60 Years"
      },
      "enrollment_count": 20,
      "start_date": "2012-06-26",
      "completion_date": "2027-12",
      "has_results": false,
      "last_update_posted_date": "2025-12-15",
      "last_synced_at": "2026-10-01T12:16:51.584Z",
      "location_count": 2,
      "location_summary": "Pittsburgh, Pennsylvania",
      "locations": [
        {
          "city": "Pittsburgh",
          "state": "Pennsylvania"
        },
        {
          "city": "Pittsburgh",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00692939"
    },
    {
      "nct_id": "NCT01350245",
      "title": "Bone Marrow Transplantation of Patients in Remission Using Partially Matched Relative Donor",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Acute Myeloid Leukemia",
        "Myelodysplastic Syndromes",
        "Biphenotypic Leukemia",
        "Acute Lymphocytic Leukemia",
        "Chronic Myeloid Leukemia",
        "Chronic Lymphocytic Leukemia",
        "Plasma Cell Neoplasms",
        "Lymphoma",
        "Hodgkin's Disease",
        "Aplastic Anemia"
      ],
      "interventions": [
        {
          "name": "Total Body Irradiation (TBI)",
          "type": "RADIATION"
        },
        {
          "name": "Donor Lymphocyte Infusion (DLI)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Cyclophosphamide",
          "type": "DRUG"
        },
        {
          "name": "Mycophenolate Mofetil (MMF)",
          "type": "DRUG"
        },
        {
          "name": "Tacrolimus",
          "type": "DRUG"
        },
        {
          "name": "Hematopoietic stem cell transplantation (HSCT)",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "RADIATION",
        "BIOLOGICAL",
        "DRUG",
        "DEVICE"
      ],
      "sponsor": "Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 28,
      "start_date": "2010-07",
      "completion_date": "2014-05",
      "has_results": true,
      "last_update_posted_date": "2025-05-16",
      "last_synced_at": "2026-10-01T12:16:51.584Z",
      "location_count": 1,
      "location_summary": "Philadelphia, Pennsylvania",
      "locations": [
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01350245"
    },
    {
      "nct_id": "NCT01744223",
      "title": "Safety Study of Gene Modified Donor T-cells Following Partially Mismatched Stem Cell Transplant",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Acute Lymphoblastic Leukemia",
        "Acute Myelogenous Leukemia",
        "Lymphoma",
        "Myelodysplastic Syndromes"
      ],
      "interventions": [
        {
          "name": "BPX-501 dose 1",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Rimiducid",
          "type": "DRUG"
        },
        {
          "name": "BPX-501 dose 2",
          "type": "BIOLOGICAL"
        },
        {
          "name": "BPX-501 dose 3",
          "type": "BIOLOGICAL"
        },
        {
          "name": "BPX-501 dose 4",
          "type": "BIOLOGICAL"
        },
        {
          "name": "SCT",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG",
        "PROCEDURE"
      ],
      "sponsor": "Bellicum Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 36,
      "start_date": "2013-03",
      "completion_date": "2032-10",
      "has_results": false,
      "last_update_posted_date": "2022-07-12",
      "last_synced_at": "2026-10-01T12:16:51.584Z",
      "location_count": 8,
      "location_summary": "Atlanta, Georgia • Buffalo, New York • New York, New York + 4 more",
      "locations": [
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Buffalo",
          "state": "New York"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "Cleveland",
          "state": "Ohio"
        },
        {
          "city": "Portland",
          "state": "Oregon"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01744223"
    },
    {
      "nct_id": "NCT02258490",
      "title": "Expanded Use of G-CSF Mobilized Donor CD34+ Selected Cells for Allogeneic Transplantation",
      "overall_status": "NO_LONGER_AVAILABLE",
      "study_type": "EXPANDED_ACCESS",
      "phases": [],
      "conditions": [
        "Chronic Myeloid Leukemia",
        "Myelodysplastic Syndrome",
        "Acute Myeloid Leukemia"
      ],
      "interventions": [
        {
          "name": "G-CSF mobilized CD34+ selected cells for transplantation",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Emory University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": null,
      "eligibility": {
        "minimum_age": "17 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "17 Years to 75 Years"
      },
      "enrollment_count": null,
      "start_date": null,
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2022-03-15",
      "last_synced_at": "2026-10-01T12:16:51.584Z",
      "location_count": 1,
      "location_summary": "Atlanta, Georgia",
      "locations": [
        {
          "city": "Atlanta",
          "state": "Georgia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02258490"
    },
    {
      "nct_id": "NCT01350232",
      "title": "Treatment of Sickle Cell Anemia With Stem Cell Transplant",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Sickle Cell Anemia",
        "Sickle Cell-hemoglobin C Disease",
        "Sickle Cell-β0-thalassemia"
      ],
      "interventions": [
        {
          "name": "Fludarabine",
          "type": "DRUG"
        },
        {
          "name": "Cytarabine",
          "type": "DRUG"
        },
        {
          "name": "Cellular Infusions",
          "type": "DEVICE"
        },
        {
          "name": "Total Body Irradiation",
          "type": "RADIATION"
        },
        {
          "name": "Cyclophosphamide",
          "type": "DRUG"
        },
        {
          "name": "Bortezomib",
          "type": "DRUG"
        },
        {
          "name": "Rituximab",
          "type": "DRUG"
        },
        {
          "name": "Plasmapheresis",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "DRUG",
        "DEVICE",
        "RADIATION",
        "PROCEDURE"
      ],
      "sponsor": "Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "45 Years",
        "sex": "ALL",
        "summary": "18 Years to 45 Years"
      },
      "enrollment_count": 2,
      "start_date": "2009-09",
      "completion_date": "2011-08",
      "has_results": true,
      "last_update_posted_date": "2025-05-16",
      "last_synced_at": "2026-10-01T12:16:51.584Z",
      "location_count": 1,
      "location_summary": "Philadelphia, Pennsylvania",
      "locations": [
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01350232"
    },
    {
      "nct_id": "NCT00429416",
      "title": "Research Study to Determine if an Experimental Agent, LLME Can Decrease the Incidence and Severity of Graft-Versus-Host-Disease (GVHD) Following Blood (Hematopoietic) Stem Cell Transplantation",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Hematologic Malignancies"
      ],
      "interventions": [
        {
          "name": "L-leucyl-L-leucine Methyl Ester (LLME)",
          "type": "DRUG"
        },
        {
          "name": "Fludarabine",
          "type": "DRUG"
        },
        {
          "name": "Cytarabine",
          "type": "DRUG"
        },
        {
          "name": "Cyclophosphamide",
          "type": "DRUG"
        },
        {
          "name": "Tacrolimus",
          "type": "DRUG"
        },
        {
          "name": "Mesna",
          "type": "DRUG"
        },
        {
          "name": "Granulocyte Macrophage Colony-Stimulating Factor (GM-CSF)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Hematopoietic stem cell transplantation (HSCT)",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "DRUG",
        "BIOLOGICAL",
        "PROCEDURE"
      ],
      "sponsor": "Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 14,
      "start_date": "2004-03",
      "completion_date": "2009-05",
      "has_results": true,
      "last_update_posted_date": "2016-11-29",
      "last_synced_at": "2026-10-01T12:16:51.584Z",
      "location_count": 1,
      "location_summary": "Philadelphia, Pennsylvania",
      "locations": [
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00429416"
    },
    {
      "nct_id": "NCT00076752",
      "title": "Lymphocyte Depletion and Stem Cell Transplantation to Treat Severe Systemic Lupus Erythematosus",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Lupus Erythematosus, Systemic"
      ],
      "interventions": [
        {
          "name": "fludarabine phosphate",
          "type": "DRUG"
        },
        {
          "name": "cyclophosphamide",
          "type": "DRUG"
        },
        {
          "name": "Rituxan (rituximab)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "filgrastim",
          "type": "BIOLOGICAL"
        },
        {
          "name": "methylprednisolone",
          "type": "DRUG"
        },
        {
          "name": "immunologic technique",
          "type": "OTHER"
        },
        {
          "name": "laboratory biomarker analysis",
          "type": "OTHER"
        },
        {
          "name": "autologous hematopoietic stem cell transplantation",
          "type": "PROCEDURE"
        },
        {
          "name": "Diphenhydramine",
          "type": "DRUG"
        },
        {
          "name": "Mesna",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG",
        "BIOLOGICAL",
        "OTHER",
        "PROCEDURE"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "15 Years",
        "maximum_age": "40 Years",
        "sex": "ALL",
        "summary": "15 Years to 40 Years"
      },
      "enrollment_count": 9,
      "start_date": "2004-01-30",
      "completion_date": "2013-10-15",
      "has_results": true,
      "last_update_posted_date": "2021-01-05",
      "last_synced_at": "2026-10-01T12:16:51.584Z",
      "location_count": 1,
      "location_summary": "Bethesda, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00076752"
    },
    {
      "nct_id": "NCT00002835",
      "title": "Combination Chemotherapy in Treating Patients With Lymphoma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Lymphoma"
      ],
      "interventions": [
        {
          "name": "Bleomycin Sulfate (BLM)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Filgrastim (G-CSF)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Recombinant Interferon Alfa",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Carmustine",
          "type": "DRUG"
        },
        {
          "name": "Cisplatin (CDDP)",
          "type": "DRUG"
        },
        {
          "name": "Cyclophosphamide",
          "type": "DRUG"
        },
        {
          "name": "Cytarabine (ARA-C)",
          "type": "DRUG"
        },
        {
          "name": "Etoposide (VP-16)",
          "type": "DRUG"
        },
        {
          "name": "Idarubicin",
          "type": "DRUG"
        },
        {
          "name": "Ifosfamide",
          "type": "DRUG"
        },
        {
          "name": "Leucovorin Calcium",
          "type": "DRUG"
        },
        {
          "name": "Melphalan",
          "type": "DRUG"
        },
        {
          "name": "Methotrexate",
          "type": "DRUG"
        },
        {
          "name": "Methylprednisolone",
          "type": "DRUG"
        },
        {
          "name": "mitoxantrone hydrochloride (DHAD)",
          "type": "DRUG"
        },
        {
          "name": "Vincristine Sulfate",
          "type": "DRUG"
        },
        {
          "name": "Peripheral Blood Stem Cell Transplantation",
          "type": "PROCEDURE"
        },
        {
          "name": "Radiation Therapy",
          "type": "RADIATION"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG",
        "PROCEDURE",
        "RADIATION"
      ],
      "sponsor": "M.D. Anderson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "15 Years",
        "maximum_age": "59 Years",
        "sex": "ALL",
        "summary": "15 Years to 59 Years"
      },
      "enrollment_count": 116,
      "start_date": "1995-10-30",
      "completion_date": "2004-02-04",
      "has_results": false,
      "last_update_posted_date": "2018-11-15",
      "last_synced_at": "2026-10-01T12:16:51.584Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00002835"
    },
    {
      "nct_id": "NCT02797470",
      "title": "Gene Therapy in Treating Patients With Human Immunodeficiency Virus-Related Lymphoma Receiving Stem Cell Transplant",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "HIV Infection",
        "Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma",
        "Plasmablastic Lymphoma",
        "Recurrent Adult Hodgkin Lymphoma",
        "Recurrent Adult Non-Hodgkin Lymphoma",
        "Recurrent Burkitt Lymphoma",
        "Recurrent Follicular Lymphoma",
        "Stage III Follicular Lymphoma",
        "Stage III Mantle Cell Lymphoma",
        "Stage IV Follicular Lymphoma",
        "Stage IV Mantle Cell Lymphoma"
      ],
      "interventions": [
        {
          "name": "Autologous Hematopoietic Stem Cell Transplantation",
          "type": "PROCEDURE"
        },
        {
          "name": "Carmustine",
          "type": "DRUG"
        },
        {
          "name": "Cytarabine",
          "type": "DRUG"
        },
        {
          "name": "Etoposide",
          "type": "DRUG"
        },
        {
          "name": "Laboratory Biomarker Analysis",
          "type": "OTHER"
        },
        {
          "name": "Lentivirus Vector CCR5 shRNA/TRIM5alpha/TAR Decoy-transduced Autologous CD34-positive Hematopoietic Progenitor Cells",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Melphalan",
          "type": "DRUG"
        },
        {
          "name": "Peripheral Blood Stem Cell Transplantation",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "PROCEDURE",
        "DRUG",
        "OTHER",
        "BIOLOGICAL"
      ],
      "sponsor": "AIDS Malignancy Consortium",
      "sponsor_class": "NETWORK",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 11,
      "start_date": "2016-06-23",
      "completion_date": "2036-03",
      "has_results": true,
      "last_update_posted_date": "2026-05-18",
      "last_synced_at": "2026-10-01T12:16:51.584Z",
      "location_count": 4,
      "location_summary": "La Jolla, California • Sacramento, California • San Francisco, California + 1 more",
      "locations": [
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "Sacramento",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02797470"
    },
    {
      "nct_id": "NCT02026934",
      "title": "CliniMACS® CD34+ Reagent System for Expanded Access Use",
      "overall_status": "NO_LONGER_AVAILABLE",
      "study_type": "EXPANDED_ACCESS",
      "phases": [],
      "conditions": [
        "Graft-Versus-Host Disease(GVHD)",
        "Anemia Due to Disturbance of Proliferation and/or Differentiation of Hematopoietic Stem Cells",
        "Graft Failure",
        "Delayed Graft Function"
      ],
      "interventions": [
        {
          "name": "CliniMACS CD34 Reagent System",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DEVICE"
      ],
      "sponsor": "Joseph Antin",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": null,
      "start_date": "2013-03",
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2016-11-21",
      "last_synced_at": "2026-10-01T12:16:51.584Z",
      "location_count": 1,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02026934"
    }
  ]
}